Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases.

Yang, Gang; Fang, Yu; Zhou, Ming; Li, Wei; Dong, Dapeng; Chen, Jing; Da, Yong; Wang, Kunpeng; Li, Xinru; Zhang, Xiaoyan; Ma, Tonghui; Shen, Ge

Yang, Gang; Fang, Yu; Zhou, Ming; Li, Wei; Dong, Dapeng; Chen, Jing; Da, Yong; Wang, Kunpeng; Li, Xinru; Zhang, Xiaoyan; Ma, Tonghui; Shen, Ge.

Afiliación

Yang G; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.
Fang Y; Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Zhou M; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.
Li W; Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Dong D; Oncology Department, Beijing Hui'an TCM-Integrated Hospital, Beijing, China.
Chen J; Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Da Y; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.
Wang K; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.
Li X; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.
Zhang X; Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Ma T; Genetron Health (Beijing) Technology, Co. Ltd., Beijing, China.
Shen G; Oncology Department, Beijing Fengtai You'anmen Hospital, Beijing, China.

Front Oncol ; 12: 948933, 2022.

Article en En | MEDLINE | ID: mdl-36052225

Palabras clave

bevacizumab; case report; combined treatment; extracranial metastases glioblastoma; pembrolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google